Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%

Core Insights - Hims & Hers Health experienced a significant decline in stock price, dropping from $70 per share in February 2025 to a precarious position a few months later, indicating potential challenges within the telehealth sector [1]. Company Overview - Hims & Hers Health was previously considered a leading company in the telehealth industry, reflecting its strong market presence and investor interest during its peak [1]. Market Context - The telehealth sector has faced volatility, as evidenced by Hims & Hers Health's dramatic stock price fluctuations, which may suggest broader industry challenges or shifts in investor sentiment [1].